Stephen Industries joins Kasvu Therapeutics’ €30 million Series A round

• Stephen Industries invested in Kasvu Therapeutics’ EUR 30 million Series A financing round.
• Kasvu develops small-molecule TrkB positive allosteric modulators designed to boost neuroplasticity without 5-HT2A-driven hallucinogenic effects.
• Lead program KTX-0141 aims to amplify endogenous BDNF signaling for neuropsychiatric and neurodegenerative disorders, including major depressive disorder.
• Proceeds target IND/CTA-enabling work, with Phase 1/1b development expected to start in H2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stephen Industries Inc Oy published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.